Medication Monitor

Generic Name (Trade Name—Company)
July 25, 2011

Immune globulin infusion (human)

(Gammagard Liquid 10%—Baxter)
New route of administration


Replacement therapy for primary humoral immunodeficiency in adult and pediatric patients 2 years of age or older

Baxter has announced FDA approval of Gammagard Liquid 10% to be administered via the subcutaneous route for patients with primary immunodeficiency. The original approval was for intravenous administration. This new route of administration will allow patients to self-administer the product at home on a weekly basis. Clinical trial data showed that subcutaneous administration of Gammagard provided similar efficacy as intravenous administration of immune globulin, with the most frequent adverse reactions of the new route of administration being local skin site reactions (2.7%).